SCHEMBL2575317

SCHEMBL2575317

O=C(O)OCc1cccc2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.59
SLC1A3 P43003 1/20 0.55
SLC1A2 P43004 1/20 0.55
SLC1A1 P43005 1/20 0.55
EPHX1 P07099 1/20 0.55
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
PARP10 Q53GL7 1/20 0.53
FFAR1 O14842 1/20 0.52
AKR1B1 P15121 1/20 0.52
CYP1A2 P05177 1/20 0.51
ATM Q13315 1/20 0.50
CTNNB1 P35222 1/20 0.50
PPARG P37231 1/20 0.50
ACP3 P15309 1/20 0.49
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
PTGER4 P35408 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21372579 0.87 TDP1 (0.56) TDP1SLC1A3SLC1A2SLC1A1EPHX1
SCHEMBL28702056 0.87 TDP1 (0.56) TDP1SLC1A3SLC1A2SLC1A1EPHX1
SCHEMBL28702058 0.86 TDP1 (0.56) TDP1SLC1A3SLC1A2SLC1A1EPHX1
SCHEMBL2575314 0.85 EPHX1 (0.55) TDP1SLC1A3SLC1A2SLC1A1EPHX1
SCHEMBL5077569 0.84 EPHX1 (0.54) TDP1SLC1A3SLC1A2SLC1A1EPHX1
SCHEMBL1998524 0.84 EPHX1 (0.54) TDP1SLC1A3SLC1A2SLC1A1EPHX1
SCHEMBL5933380 0.84 EPHX1 (0.54) TDP1SLC1A3SLC1A2SLC1A1EPHX1
SCHEMBL5933367 0.84 EPHX1 (0.54) TDP1SLC1A3SLC1A2SLC1A1EPHX1
SCHEMBL1998527 0.84 MEN1 (0.59) TDP1SLC1A3SLC1A2SLC1A1EPHX1
SCHEMBL487420 0.84 KMT2A (0.55) TDP1SLC1A3SLC1A2SLC1A1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109937197-B Electrochemical process for preparing aryl alkyl carbonates and diaryl carbonates 科思创德国股份有限公司 2022-05-03 CN disclosed
CN-109311915-B Sulfonium salt, thermal or photoacid generator, thermal or photocurable composition, and cured product thereof 三亚普罗股份有限公司 2021-09-14 CN disclosed
EP-3541778-A1 ELECTROCHEMICAL METHOD FOR PRODUCING ARYL ALKYL CARBONATES AND DIARYL CARBONATES Covestro Deutschland AG (DE) 2019-09-25 EP disclosed
WO-2019078171-A1 METHOD FOR CONCENTRATING OR SEPARATING POLYMER COMPOUND 国立大学法人京都大学 2019-04-25 WO disclosed
EP-2497475-A1 Treatment of laminitis with platelet aggregation inhibitors Dussler, Sabine (DE) 2012-09-12 EP disclosed
US-8048897-B2 Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-01 US disclosed
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-12-25 US disclosed
EP-1783110-A1 NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-09 EP disclosed
US-20060088786-A1 Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus MITSUI CHEMICALS, INC. (JP) 2006-04-27 US disclosed
EP-1484191-A1 REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE Sony Corporation (JP) 2004-12-08 EP disclosed
EP-0542411-B1 TETRAHYDROTHIENOPYRIDINE DERIVATIVES, FURO AND PYRROLO ANALOGS THEREOF AND THEIR PREPARATION AND USES FOR INHIBITING BLOOD PLATELET AGGREGATION SANKYO CO (JP) 1998-08-12 EP disclosed
US-5691319-A ANTICARCINOGENIC AGENTS SANKYO COMPANY, LIMITED (JP) 1997-11-25 US disclosed
EP-0536936-B1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use SANKYO CO (JP) 1996-08-14 EP disclosed
US-5389626-A 3-aryloxmethyl-cephalosporin derivatives, and their medical use SANKYO COMPANY, LIMITED (JP) 1995-02-14 US disclosed
US-5288726-A Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation UBE INDUSTRIES LIMITED (JP) 1994-02-22 US disclosed
EP-0542411-A2 Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation Sankyo Company Limited (JP) 1993-05-19 EP disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 EP disclosed
EP-0363223-A2 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use Sankyo Company Limited (JP) 1990-04-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060088786-A1 Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus ALPG, TRPC6, GNRHR TDP1 316/4885SLC1A3 599/4885SLC1A2 260/4885
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes SLC5A1, GPR119, SLC5A2 TDP1 3080/4885SLC1A3 1541/4885SLC1A2 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.